Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Piramal Imaging SA Identifier:
First received: September 9, 2008
Last updated: May 10, 2013
Last verified: May 2013

The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for visually assessing and diagnosing Alzheimer's disease.For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day.The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers.The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations

Condition Intervention Phase
Alzheimer Disease
Amyloid Beta-Protein
Drug: Florbetaben (BAY94-9172)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer178s Disease Compared to Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Piramal Imaging SA:

Primary Outcome Measures:
  • To determine the sensitivity and specificity of the independent visual assessment of detecting/excluding cerebral amyloid beta [ Time Frame: Two separate scanning periods will be performed after IMP injection ] [ Designated as safety issue: No ]
  • To determine the sensitivity and specificity of the independent visual assessment of detecting/excluding cerebral amyloid beta. The clinical diagnosis in Part B will be established by an independent consensus panel (CP)of experts in dementia [ Time Frame: Two separate scanning periods will be performed after IMP injection ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the usefulness of two additional imaging windows for the visual assessment [ Time Frame: Two separate scanning periods will be performed after IMP injection ] [ Designated as safety issue: No ]
  • To evaluate the proposed visual assessment procedure and subsequent classification [ Time Frame: Two separate scanning periods will be performed after study product injection ] [ Designated as safety issue: No ]
  • To assess various quantitative PET image analysis methods [ Time Frame: Two separate scanning periods will be performed after study product injection 7 days ] [ Designated as safety issue: No ]
  • To evaluate the safety and tolerability [ Time Frame: Two seperate scanning periods will be performed after IMP injection ] [ Designated as safety issue: Yes ]
  • To determine the sensitivity specificity of both, volume of interest (VOI) and voxol based quantitative image analysis in detecting/excluding cerebral beta-amyloid when compared to the independent CP diagnosis as the standard of truth [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • To confirm the safety profile of a single dose of BAY94-9172(ZK6013443) in patients with probable AD and HVs [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]

Enrollment: 422
Study Start Date: August 2008
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Florbetaben (BAY94-9172)
Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions


Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:

    • Is a man or woman and is > 55 of age, whereby females must be without childbearing potential (confirmed by either: age >/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
    • Has at least 6 years of education
    • Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures
    • Possesses a general health that permits adequate compliance with all study procedures
    • The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
    • Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
  • Inclusion criteria for HV only:

    • Has no evidence of cognitive impairment
    • Has MRI brain scan that has been judged as "normal" (age- appropriate)
  • Inclusion criteria for patients with AD only:

    • Presents with positive assessment for dementia of Alzheimer's type
    • Does not fulfill the criteria DLB or VaD
    • MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
    • Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver

Exclusion Criteria:

  • Has any contraindication to MRI examination scan
  • Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
  • Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
  • is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
  • Has a history of exposure to any radiation >15 mSv/year (e.g. occupational or radiation therapy)
  • Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
  • Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
  • Has a brain tumor or other intracranial lesion, a disturbance of CSF circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
  • Has an inflammatory or infectious CNS disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease
  • Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
  • Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
  • Has a history of alcohol or drug abuse
  • Has history of severe persistent depression
  Contacts and Locations
Please refer to this study by its identifier: NCT00750282

United States, Arizona
Sun City, Arizona, United States, 85351
United States, California
Stanford, California, United States, 94305
United States, Connecticut
New Haven, Connecticut, United States, 06510
United States, New York
Bronx, New York, United States, 10461
New York, New York, United States, 10016
New York, New York, United States, 10032
United States, Rhode Island
Providence, Rhode Island, United States, 02906
Australia, New South Wales
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Heidelberg, Victoria, Australia, 3084
Erlangen, Bayern, Germany, 91054
München, Bayern, Germany, 81675
München, Bayern, Germany, 81377
Essen, Nordrhein-Westfalen, Germany, 45122
Jülich, Nordrhein-Westfalen, Germany, 52425
Münster, Nordrhein-Westfalen, Germany, 48149
Dresden, Sachsen, Germany, 01307
Leipzig, Sachsen, Germany, 04103
Berlin, Germany, 13125
Kobe, Hyogo, Japan, 650-0017
Kobe, Hyogo, Japan, 650-0047
Bunkyo-ku, Tokyo, Japan, 113-8603
Zürich, Switzerland, 8091
Sponsors and Collaborators
Piramal Imaging SA
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided by Piramal Imaging SA

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Piramal Imaging SA Identifier: NCT00750282     History of Changes
Other Study ID Numbers: 91708, 2007-002256-42, 311741
Study First Received: September 9, 2008
Last Updated: May 10, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Switzerland: Swissmedic
Australia: Department of Health and Ageing Therapeutic Goods Administration
Japan: Pharmaceuticals and Medical Devices Agency
United States: Food and Drug Administration

Keywords provided by Piramal Imaging SA:
Alzheimer Disease
Amyloid beta-Protein

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders processed this record on April 17, 2014